MDM2 and liposarcoma: Accumulating evidence has suggested that the matched targeted therapy approach can demonstrate better clinical outcomes than a nonmatched approach, but this implies the need to select patients for the relevant aberration.34-37 Wagner et al21 showed that responses with MK-8242 (MDM2 inhibitor) were exclusively observed in patients with liposarcoma (RR, 11.1% [three or 27]) whose molecular hallmark includes MDM2 amplification5 (nonliposarcoma; RR, 0% [zero of 14]).